Raymond James Financial Services Advisors, Inc. Jounce Therapeutics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

  • $73.5 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 12, 2021
SELL
$6.37 - $10.33 $79,159 - $128,370
-12,427 Closed
0 $0
Q3 2020

Nov 04, 2020
SELL
$4.58 - $10.95 $23,825 - $56,961
-5,202 Reduced 29.51%
12,427 $101,000
Q2 2020

Jul 17, 2020
BUY
$4.17 - $7.58 $73,512 - $133,627
17,629 New
17,629 $122,000

Others Institutions Holding JNCE

# of Institutions
4
Shares Held
720K
Call Options Held
0
Put Options Held
0
View Full List

About Jounce Therapeutics, Inc.

JNCE Quotes by TradingView
  • Ticker JNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,694,200
  • Description
  • Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...
More about JNCE
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email